Top Markets
Coin of the day
Pharma Mar, S.A. Pharma Mar, S.A.

Pharma Mar, S.A.

PHM
Rank in Stocks #7110
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and... Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Share Price
$99.16
Last synced: 2026-08-27
Market Cap
$1.72B
Change (1 day)
0.00%
Change (1 year)
2.52%
Country
ES
Trade Pharma Mar, S.A. (PHM)

Category

P/S ratio for Pharma Mar, S.A. (PHM)
P/S ratio as of 2026 TTM: 0
According to Pharma Mar, S.A. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Pharma Mar, S.A. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH